ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AFFX Stock Price » AFFX Stock News

Affymetrix Share News

 Affymetrix (mm) Stock Price
AFFX Stock Price
 Affymetrix (mm) Stock Chart
AFFX Stock Chart
 Affymetrix (mm) Stock News
AFFX Stock News
 Affymetrix (mm) Company Information
AFFX Company Information
 Affymetrix (mm) Stock Trades
AFFX Stock Trades

Illumina Problems Cast Shadow Over Biotech Sector

--Illumina stock down nearly 32% Friday --Warns on third-quarter revenue and withdraws full-year estimates --Peers take tumble too but most aren't seen as tied to government research funding By Russ Britt A dire revenue warning from biotech firm Illumina Inc. (ILMN) swept away nearly a third of the company's market value Friday and caused other players in the sector to tumble as investors feared the worst. Illumina plummeted nearly 32% to $27.22 in midday trading. The company warned Thursday night that it expected third-quarter revenue to be about $235 million, well off the $278 million projected by Wall Street analysts. It also said it wouldn't provide future forecasts and was withdrawing its full-year estimates. Illumina cited uncertainty over research funding in the U.S. and Europe as well as excess capacity and drops in purchased upgrades of its Genome Analyzer equipment. "In the quarter, we saw what we believe to be an unprecedented slowdown in purchasing due to uncertainties in research funding and overall economic conditions, as well as a temporary excess of sequencing capacity in the market," Jay Flatley, Illumina's chief executive, said in a written statement. "We expect these conditions to continue through at least the fourth quarter, while the 2012-2013 U.S. budgets for [the National Institutes of Health] and other related agencies are determined." The news caused a panic among investors in other medical-research-gear makers, including Agilent Technologies Inc. (A), Waters Corp. (WAT), Thermo Fisher Scientific Inc. (TMO), Life Technologies Corp. (LIFE), Human Genome Sciences Inc. (HGSI), PerkinElmer Inc. (PKI) and Affymetrix Inc. (AFFX). All were down 6% or more in recent action, with PerkinElmer and Affymetrix off nearly 9%. Illumina reportedly gets 80% of its funding through government sources, but the average of the others is somewhat lower, said Bryan Brokmeier, an analyst with Maxim Group. Concerns over the drying up of government funding for research have sent Illumina shares plunging from an intraday high of more than $78 reached in July. Illumina's warning, while not unexpected, was a surprise in its severity, Brokmeier said. "This was worse than what people were expecting," he said. Although the company had been considered one of the premier providers of research gear, a slew of analysts cut their rating on the company's shares Friday, including Brokmeier, who downgraded Illumina to hold from buy. Deutsche Bank's Ross Muken did the same and lowered his price target from $52.50 to $30. "The magnitude of [Illumina's] miss will come as a surprise to many and the implication that [the fourth quarter] and [first half of 2012] revenue will be barely growing should serve to keep the stock within a depressed range [for the medium term]," Muken said in a note. -Russ Britt; 415-439-6400; AskNewswires@dowjones.com

Stock News for Affymetrix (AFFX)
DateTimeHeadline
05/20/201306:52:34Affymetrix Names Gavin Wood Chief Financial Officer
04/09/201309:11:12U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
01/08/201318:00:14Affymetrix to Restructure; Financial Chief to Retire
02/09/201208:50:07US STOCK FUTURES: HOT STOCKS TO WATCH
10/07/201115:01:13Illumina Problems Cast Shadow Over Biotech Sector
05/09/201109:34:27Affymetrix Gene-Expression Reagents Win FDA Clearance; Shares...
12/21/200910:02:23H1N1 Test With Affymetrix Technology Gets FDA Approval

Affymetrix and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad